drug:eloralinitide
Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
company:eli-lilly
company:eli-lilly
Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
drug:retatrutide
An update on Retatrutide (May 2025)
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
company:eli-lilly
Eli Lilly suing GLP1 compounders & related companies
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
drug:mounjaro
Mounjaro's India launch
Eli Lilly's Mounjaro launches in India
category:news
Oral pill Orforglipron delivers stellar results in Phase 3 Trial
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
politics
2025 Trump Tariffs on Pharmaceutical Imports
Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
category:news
Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
category:watercooler
Shortages threaten corporate profits, likely to end soon
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:howto
What's the best injection site for GLP1s?
What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.
category:benefits
Zepbound coverage for Sleep Apnea gets Agency approval
Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
company:eli-lilly
Eli Lilly brands GLP1s as "anti-hedonics"
Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"